Anti-mullerian Hormone Serum Level as a Predictor of Responsiveness to Clomiphene Citrate Therapy in Iraqi Women with PCOS

Dhai Rashid; Raghda Bardan

doi:10.3889/oamjms.2022.8691

Authors

Dhai Rashid Department of Obstetrics and Gynecology, College of Medicine, Al-Anbar University, Ramadi, Iraq https://orcid.org/0000-0003-3935-6840
Raghda Bardan Department of Obstetrics and Gynecology, College of Medicine, Al-Anbar University, Ramadi, Iraq https://orcid.org/0000-0003-4222-0610

DOI:

https://doi.org/10.3889/oamjms.2022.8691

Keywords:

Anti-Müllerian hormone, Clomiphene citrate, Ovulation prediction, Polycystic ovarian syndrome

Abstract

BACKGROUND: Ovulation induction in polycystic ovarian syndrome is one of the most common interventions used in the treatment of infertility and prediction of the response is very important. Although the serum anti-mullerian hormone (AMH) concentrations are known to be a reliable predictor of ovarian response in in vitro fertilization, in women with polycystic ovary syndrome (PCOS) with a higher level of AMH ovulation induction by clomiphene citrate may be not enough to increase the level of follicle-stimulating hormone and reduce the intraovarain AMH to a level that compatible with the restoration of ovulation.

AIM: Our study aimed to identify those females who will respond to treatment and the starting dose of anti-mullerian hormone serum level as a predictor of responsiveness to clomiphene citrate therapy in Iraqi women with PCOS.

METHODS: 79 females with polycystic ovarian syndrome were included in the study. AMH serum concentrations were determined on the second or 3^rdday of the early follicular phase of the menstrual cycle before initiating clomiphene citrate in the first treatment cycle.

RESULTS: The females were falling-out into two groups according to their response to treatment. The patient who ovulated had a significantly lower AMH level among responders 7.89 +−3.2 compared to non-responder 9.41 +−3.27. The women who responded at 50 mg dose had lower AMH 6.56 +−2.2 compared to women who responded at 100mg clomiphene citrate had AMH of 8.74 +−3 with optimum cutoff value for AMH is 6.25 to respond.

CONCLUSION: Serum AMH level measurement prior to treatment initiation in women with PCOS may be a useful method for predicting the outcome of clomiphene citrate treatment, and for each specific ethnic group, there is a cutoff value for AMH above which the response to clomiphene citrate is impaired.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Keith D, editor. Nick raine‐fenning. subfertility, reproductive problems. In: Edmonds, Christoph Lees and Tom Bourne. Dewhurst’s Textbook of Obstetrics and Gynaecology. 9th ed. London, UK: Wiley Blackwell; 2018: 691. Available from: https://www.goodreads.com/book/show/42190959-dewhurst-s-textbook-of-obstetrics-gynaecology [Last accessed on 2021 Dec 12].

Dun EC, Nezhat CH. Tubal factor infertility: Diagnosis and management in the era of assisted reproductive technology. Obstet Gynecol Clin North Am. 2012;39(4):551-66. https://doi.org/10.1016/j.ogc.2012.09.006 PMid:23182560

Tanbo T, Mellembakken J, Bjercke S Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018;97(10):1162-7. https://doi.org/10.1111/aogs.13395 PMid:29889977

Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018;15(11):2589. https://doi.org/10.3390/ijerph15112589 PMid:30463276

Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives. Appl Clin Genet. 2019;12:249-60. https://doi.org/10.2147/TACG.S200341 PMid:31920361

Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520. https://doi.org/10.1210/er.2015-1104 PMid:27459230

Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545-73. https://doi.org/10.1210/js.2019-00078 PMid:31384717

Dumont A, Robin G, Catteau-Jonard S, Dewailly D. Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: A review. Reprod Biol Endocrinol. 2015;13:137. https://doi.org/10.1186/s12958-015-0134-9 PMid:26691645

Almeida FR, Costermans NG, Soede NM, Bunschoten A, Keijer J, Kemp B, et al. Presence of anti-Müllerian hormone (AMH) during follicular development in the porcine ovary. PLoS One. 2018;13(7):e0197894. https://doi.org/10.1371/journal.pone.0197894 PMid 30063719

Cook-Andersen H, Chuan SS, Maas K, Rosencrantz MA, Su HI, Lawson M, et al. Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(1):251-7. https://doi.org/10.1210/jc.2014-2948 PMid:25303490

Mumford SL, Legro RS, Diamond MP, Coutifaris C, Steiner AZ, Schlaff WD, et al. Baseline AMH level associated with ovulation following ovulation induction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2016;101(9):3288-96. https://doi.org/10.1210/jc.2016-1340 PMid:27228369

Perales-Puchalt A, Legro RS. Ovulation induction in women with polycystic ovary syndrome. Steroids. 2013;78(8):767-72. https://doi.org/10.1016/j.steroids.2013.05.005 PMid:23707553

Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A, et al. The treatment of infertility in polycystic ovary syndrome: A brief update. Aust N Z J Obstet Gynaecol. 2012;52(4):400-3. https://doi.org/10.1111/j.1479-828X.2012.01448.x PMid:22639834

Costello MF, Misso ML, Balen A, Boyle J, Devoto L, Garad RM, et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: Assessment and treatment of infertility. Hum Reprod Open. 2019;2019(1):hoy021. https://doi.org/10.1093/hropen/hoy021 PMid:31486807

Choi MH, Yoo JH, Kim HO, Cha SH, Park CW, Yang KM, et al. Serum anti-Müllerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clin Exp Reprod Med. 2011;38(3):153-8. https://doi.org/10.5653/cerm.2011.38.3.153 PMid:2238443

Dąbkowska-Huć A, Lemm M, Sikora J, Witek A, Skałba P. Anti-Müllerian hormone dynamics during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Endokrynol Pol. 2013;64(3):203-7. PMid:23873424

Dewailly D, Barbotin AL, Dumont A, Catteau-Jonard S, Robin G. Role of Anti-Müllerian hormone in the pathogenesis of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2020;11:641. https://doi.org/10.3389/fendo.2020.00641 PMid:33013710

Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. The predictive value of circulating anti-Müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: A prospective observational study. J Clin Endocrinol Metab. 2013;98(10):4170-5. https://doi.org/10.1210/jc.2013-2193 PMid:23979947

Xi W, Yang Y, Mao H, Zhao X, Liu M, Fu S. Circulating anti-Mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome. J Ovarian Res. 2016;9:3. https://doi.org/10.1186/s13048-016-0214-2 PMid:26864649

Gülşen MS, Ulu İ, Köpük ŞY, Kıran G. The role of anti- Müllerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2019;35(1):86-9. https://doi.org/10.1080/09513590.2018.1499085 PMid:30044165